Skip to main content

Peptide Pharmacology

Menu

GLOW Blend

Contents

What is GLOW blend?

A peptide blend combines more than one peptide together to produce additive, and sometimes synergistic, effects.

The GLOW blend is a combination of three peptides: GHK-Cu, TB4 (or TB-500), and BPC-157

What is GLOW blend?

GLOW contains the following peptides:

BPC-157 is a peptide that influences multiple biological pathways involved in healing and tissue repair. It interacts with the body’s nitric oxide system to help regulate blood flow and inflammation, supports the formation of new blood vessels (angiogenesis), and promotes cellular migration to help cells move to injured areas and rebuild damaged structures. It has also shown potential in protecting nerves and supporting nerve regeneration in animal models.

Thymosin beta 4 (TB4) is a naturally occurring peptide found in nearly every cell in the human body, encoded by a gene on the X chromosome. Its primary role is to bind to actin, a key microfilament in the cytoskeleton, helping reorganize the cell’s structural framework and influence how cells move. Research has shown that TB4 plays an important role in tissue repair, helping cells migrate to the site of injury so they can rebuild and heal damaged tissue. TB-500 can be used instead of TB4 in the KLOW blend, and it offers similar advantages.

GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It has been studied extensively for its role in tissue repair, skin health, and anti-inflammatory processes. Interest in GHK-Cu has grown due to its apparent ability to signal regeneration without overstimulating growth pathways. 

When combined together, the components of GLOW promote healing of injured tissues in a synergistic fashion, suppress inflammation, and maintain skin health.  

What is GLOW Blend Used For?

  • Wound healing and tissue repair, especially muscles, tendons, ligaments
  • Reducing inflammation
  • Joint support: By supporting connective tissue repair, this combination may play a role in joint recovery following injury.
  • Nerve protection: Experimental models suggest potential benefits in nerve healing and protection after trauma.
  • Wound healing
  • Skin rejuvination

Side Effects of GLOW Blend

Limited data shows that BPC-157, TB4, and GHK-Cu individually are well-tolerated with minimal side effects. Most of the side effects have been due to the injection rather than the peptides. Please see the pages for BPC-157, TB4 , and GHK-Cu for more details.

The most common side effect is injection site pain or reactions, most often attributed to the GHK-Cu component.

GLOW Blend Dosing Protocol (for Research)

GLOW formulations usually contain the peptides in the following amounts: 

GHK-Cu: 50 mg

BPC 157: 10 mg

TB4 (or TB-500): 10 mg

The total is therefore 70 mg. The suggested research protocol below is based on the composite vial (70 mg), and not for the individual doses:

  • 1Week 1: 2 mg daily (2 mg total, which adds up to 1.42 mg GHK-Cu and 0.285 mg of each of GHK-Cu and TB4 (or TB-500))
  • 2Week 2 and beyond: 4 mg daily (4 mg total, which adds up to 2.84 mg GHK-Cu and 0.57 mg of each of GHK-Cu and TB4 (or TB-500))
Click here to learn how to prepare peptides for research

Recommended GLOW blend Source (for Research)

GenPeptide.com

References

Sikiric P, et al. Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal and extra-intestinal healing. Curr Pharm Des. 2011;17(16):1612–1632.

View Source

Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19:969-88. doi: 10.1163/156856208784909435.

View Source

Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988 Oct 10;238(2):343-6. doi: 10.1016/0014-5793(88)80509-x.

View Source

Pickart L, et al. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018 Jul 7;19(7):1987. doi: 10.3390/ijms19071987.

View Source

Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-5. doi: 10.2174/13816128113199990421. PMID: 23782145.

View Source

Xue B, et al. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):E4596-605.

View Source

Sosne G, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022 Dec 29;24(1):554.

View Source

Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021 Sep;25(17):8222-8228.

View Source